ARDX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AR

Mkt Cap

$796.5M

Volume

4.92M

Next Earnings

October 29th

Loading chart

AR

ARDXArdelyx, Inc.

ARDX

Pay with—

Available Balance0.00

AR

Mkt Cap

$844.3M

Volume

4.92M

Next Earnings

October 29th

Chart Financials Earnings News About Insider Filings

ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawSchall, Brown & Schwartz LLP has filed a class action lawsuit against Ardelyx, Inc. for alleged securities violations. The lawsuit claims the company made false and misleading statements regarding reimbursement barriers and patient access issues for its drugs XPHOZAH and IBSRELA, which impacted commercial performance. The class period spans January 13, 2025 to August 6, 2026, with a deadline of November 16, 2026 for shareholders to participate.GlobeNewswire Inc. · Oct 16, 2026

Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor HarmA class action lawsuit has been filed against Ardelyx, Inc. for alleged securities fraud. The complaint alleges that the company made false and misleading statements regarding payer access barriers, prior authorization requirements, and commercial performance of its drugs XPHOZAH and IBSRELA during the period from January 13, 2025 to August 6, 2026. Investors have until November 16, 2026 to request lead plaintiff status.GlobeNewswire Inc. · Oct 15, 2026

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDXRosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages.GlobeNewswire Inc. · Oct 14, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AVXLRosen Law Firm is reminding investors in Anavex Life Sciences, Ardelyx, and AST SpaceMobile to join securities class action lawsuits before upcoming deadlines. The lawsuits allege that these companies made false or misleading statements regarding their business operations, internal controls, and regulatory challenges. Investors who purchased securities during specified class periods may be entitled to compensation.GlobeNewswire Inc. · Oct 11, 2026

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDXRosen Law Firm is soliciting investors who purchased securities of Ardelyx, Inc., Anavex Life Sciences Corp., and AST SpaceMobile, Inc. during specified periods to join class action lawsuits. The firm alleges these companies made materially false statements regarding commercial performance and growth prospects. Investors have until November 16, 2026 to serve as lead plaintiffs.GlobeNewswire Inc. · Oct 11, 2026

New Strong Sell Stocks for October 9thZacks has added three stocks to its Strong Sell list: Accendra Health (ACH), Ardelyx (ARDX), and Draganfly (DPRO). All three companies have experienced significant downward revisions to their earnings estimates over the past 60 days, with ACH seeing a 109.4% downward revision, ARDX a 25% revision, and DPRO a 59.6% revision.Zacks Investment Research · Oct 9, 2026

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDXRosen Law Firm is urging investors who purchased Ardelyx common stock between January 13, 2025 and August 6, 2026 to join a securities class action lawsuit. The lawsuit alleges that Ardelyx provided misleading statements about its commercial performance and concealed material facts regarding reimbursement barriers and access issues for its drugs XPHOZAH and IBSRELA, resulting in investor damages.GlobeNewswire Inc. · Oct 9, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSRosen Law Firm has filed securities class action lawsuits against Hims & Hers Health, Duolingo, and Ardelyx. The Hims lawsuit alleges the company made false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased securities during specified class periods are encouraged to join the litigation before the November 2, 2026 lead plaintiff deadline.GlobeNewswire Inc. · Oct 9, 2026

New Strong Sell Stocks for October 7thZacks has added three stocks to its Strong Sell list today: Ardelyx (ARDX), a biopharmaceutical company with a 53.9% downward earnings revision; Southwest Airlines (LUV), a passenger airline with a 4.1% downward earnings revision; and Collegium Pharmaceutical (COLL), a specialty pharmaceutical company with a nearly 3% downward earnings revision over the last 60 days.Zacks Investment Research · Oct 7, 2026

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Baidu, Inc. (BIDU), Ardelyx, Inc. (ARDX), and Better Home & Finance Holding Company (BETR) Announced by Holzer & Holzer, LLCHolzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against Baidu, Ardelyx, and Better Home & Finance Holding Company. The lawsuits allege materially false and misleading statements regarding business operations and financial projections. Investors who purchased shares during specified periods and suffered losses are encouraged to seek legal representation.GlobeNewswire Inc. · Oct 6, 2026

to start trading

AR

ARDXArdelyx, Inc.

ARDX

Pay with—

Available Balance0.00

Your PositionYou don't own any ARDX yet.

Related Tickers

Earnings